ADMA (asymmetric dimethylarginine): An atherosclerotic disease mediating agent in patients with renal disease?

Nephrology Dialysis Transplantation

Volumn 16, Issue 9, 2001, Pages 1742-1745

  Kielstein, Jan T ^a   Frölich, Jürgen C ^a   Haller, Hermann ^a   Fliser, Danilo ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

ADMA; Atherosclerosis; Nitric oxide; Renal disease

Indexed keywords

HOMOCYSTEINE; METHIONINE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE;

AMINO ACID BLOOD LEVEL; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CONTROLLED STUDY; HEMODIALYSIS; HUMAN; HUMAN CELL; KIDNEY DISEASE; KIDNEY FAILURE; MORBIDITY; MORTALITY; PATHOGENESIS; PRIORITY JOURNAL; URINARY EXCRETION; VASCULAR ENDOTHELIUM; VASODILATATION;

EID: 0034838891     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/16.9.1742     Document Type: Article

References (32)

1. Does ADMA cause endothelial dysfunction?
2. The L-arginine-nitric oxide pathway
3. Nitric oxide synthase isozymes. Characterization, purification, molecular cloning, and functions
4. Peptides with sequences similar to glycine, arginine-rich motifs in proteins interacting with RNA are efficiently recognized by methyl-transferase(s) modifying arginine in numerous proteins
5. Protein-arginine methyl-transferase I, the predominant protein-arginine methyltransferase in cells, interacts with and is regulated by interleukin enhancer-binding factor 3
6. Metabolism of methylarginines by human vasculature; implications for the regulation of nitric oxide synthesis
7. Characterization of human umbilical vein endothelial cell lines produced by transfection with the early region of SV40
8. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure
9. Studies on the catabolism of Ng-methyl-arginine, Ng, Ng-dimethylarginine and Ng, Ng-dimethylarginine in the rabbit
10. Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases
11. Response of cerebral blood vessels to an endogenous inhibitor of nitric oxide synthase
12. Effects of some guanidino compounds on human cerebral arteries
13. Regional and cardiac haemodynamic effects of NG, NG,dimethyl-L-arginine and their reversibility by vasodilators in conscious rats
14. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease
15. Asymmetric dimethylarginine (ADMA): A novel risk factor for endothelial dysfunction: Its role in hypercholesterolemia
16. Endogenous nitric oxide synthase inhibitor: A novel marker of atherosclerosis
17. Independent association of asymmetric dimethylarginine (ADMA) with the presence and severity of coronary artery disease
18. How many patients with renal insufficiency survive until end-stage renal failure?
19. Atherosclerosis and arteriosclerosis in chronic renal failure
20. Premature cardiovascular disease in chronic renal failure
21. Altered flow-dependent vasodilatation of conduit arteries in maintenance haemodialysis
22. Physiology and biochemistry of endothelial function in children with chronic renal failure
23. Endothelium-dependent relaxation of small resistance vessels is impaired in patients with autosomal dominant polycystic kidney disease
24. Hemodialysis and L-arginine, but not D-arginine, correct renal failure-associated endothelial dysfunction
25. Nitric oxide production is reduced in patients with chronic renal failure
26. Indices of activity of the nitric oxide system in hemodialysis patients
27. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: Relationship to treatment method and atherosclerotic disease
28. Serum levels of NG, NG-dimethyl-L-arginine, a potential endogenous nitric oxide inhibitor in dialysis patients
29. Concentration of dimethyl-L-arginine in the plasma of patients with end-stage renal failure
30. Colocalization of demethylating enzymes and NOS and functional effects of methylarginines in rat kidney
31. Asymmetric dimethylarginine (ADMA): An endogenous inhibitor of NO synthase predicts mortality in patients with end-stage renal disease
32. Renoprotection by nitric oxide donor and lisinopril in the remnant kidney model